OR WAIT 15 SECS
Managing KOLs effectively
You can never be 'too digital'
Europe - a future leader in vaccines?
Is Mobile Health just for mobile people?
Recipes for Success in India and China
Why Scotland is at the forefront of life sciences investment
Accessing the Pharmerging Markets
Global Compliance in the Pharmerging Markets
The Trouble with Stakeholders
Parallel Trade in Greece and Spain
The Zombie Economy
Choosing the Right Executive for China
The Top 50 Pharma Companies
EMA concerns over NICE
Market access in Spain
EU counterfeit crossroads
Social media — a patient's story
Market access in Italy
Blockbusters are alive and well
Starting out with social media
Market access in France
Listening to social media
3D competitive analysis
Market access in the UK
Do you need a social media director
Staying ahead of the technology curve
Why is the US free market so expensive?
Managing a drug crisis
New Merck's race for the emerging markets
Using the web to improve patient compliance
Nycomed's Big Pharma plans
A chronic fatigue syndrome breakthrough?
Run your sales territory as a standalone business
The lowdown of Shire
Is there life after Big Pharma?
Don't get lost in translation
The future of NICE
The EU versus animal experimentation
The seven deadly sins of marketing
Information to patients
Reinventing market research
Named patient programmes
Pharma to 2020
IMI UPdate with Jonathan Knowles
The art and science of marketing
Pipeline report 20100
Recruting and retaining R&D staff in a recession
All change at the EU
25 November 2009
M&As in 2009 - Pharma’s rollercoaster year
What can pharma learn from Toyota?
Achieve more by spending - and doing - less
11 November 2009
What will transparency mean for pharma’s reputation?
Addressing the French funding crisis
Changing the rules
Overcoming ‘them and us’ thinking
28 October 2009
Industry drug lobbyists come out on top
Daniel Vasella, the inside story
14 October 2009
CROs and pharma: a dangerously equal partnership?
Social Media: Pharma’s black hole?
Executives: It’s time to put away childish things
30 September 2009
The obesity pipeline - a fat chance of success?
The Innovative Medicines Initiative - is it working?
What IMI round 2 means for IT
15 September 2009
Takeda takes on Europe
Trust is more than a marketing issue
The new hot topics in supply chain management
Straddling or focusing: the moment of truth
2 September 2009
Boost your North American business
Shark proof your product launch
Harmony in the EU?
26 August 2009
What's the deal at Solvay?
The power of medical animation
18 August 2009
Need a new non-executive director?
Sweden takes the EU reins
Patent litigation insurance: a win-win situation
11 August 2009
Seven steps to a successful global brand
EU and FDA: working together on drug approval
Profile: Erin Gainer, HRA Pharma
5 August 2009
Chris Viehbacher: Staging a French revolution at Sanofi-Aventis
Recession proof companies Part II: Norgine
Belgium's statin plan backfires
28 July 2009
In search of recession-proof companies: Part 1
Why pharma should embrace multi-level competition
Biotech and health outcomes in 2030
21 July 2009
The EC antitrust report results are in. Time to pop open the champagne?
The antitrust report: a legal perspective
A quick guide to the EU's new pharmacovigilance package
Does Big Pharma still exist?
14 July 2009
Novartis: Why we can't give free flu vaccines to poor countries
Nycomed: licensing for long-term success
Keeping up with KOLs
7 July 2009
Big Pharma isn't dead, but long live small pharma?
Where's all the specialty pharma data?
Social media CAN work for pharma
30 June 2009
Is the online revolution working for pharma?
Tackling neglected diseases
23 June 2009
'Pharmerging' markets and the new world order
Finding the perfect pharma match
New EU committee leaves member states out in the cold
17 June 2009
Why are doctors so down on pharma? A 2009 survey
Smart out-licensing to survive the 'shake-out'
Too much market focus can be a bad thing
10 June 2009
IMI's winners and losers
Knock 'em dead with your website press centre
UK Biotech: situation critical
3 June 2009
Belgian innovation: truffles or waffle?
Opportunities in Vietnam
New pathways in R&D
27 May 2009
So, EFPIA, where's the innovative thinking, then?
Don't miss the e-Marketing boat
Only the bad times are good for pharma
20 May 2009
The World's top 50 pharma companies
13 May 2009
The end of European healthcare as we know it?
Biosimilars in Europe: the story so far
Strategy solutions - the answers are out there
6 May 2009
Breaking the glass ceiling - a report on women in pharma
Reading the 'risk radar'